Subjective Vertical Position Allows Prediction of Postural Deterioration in Patients with Parkinson’s Disease

Table 4

Clinical assessment values upon enrollment (baseline) and after 1 year of follow-up.

	Baseline	1 year	value
mH&Y score	2.5 ± 0.6	2.5 ± 0.7	0.7
UPDRS I	2.2 ± 1.6	2.4 ± 1.7	0.7
UPDRS II	8.6 ± 6.0	6.7 ± 3.9	0.3
UPDRS III	14.2 ± 9.4	16.5 ± 9.9	0.4
UPDRS IV	2.4 ± 2.8	2.2 ± 2.1	0.7
UPDRS total	27.3 ± 13.7	27.8 ± 13.8	0.9
MMSE	28.3 ± 1.7	26.9 ± 2.3	0.008
FFT angle (°)	12.8 ± 12.9	13.9 ± 9.8	0.6
SV angle (°)	6.0 ± 9.8	11.0 ± 6.1	0.02
LED (mg/day)	636 ± 199.4	939 ± 368.4	0.001
Dopamine agonist (%)	100	94.4	0.5

Mean ± SD values are shown. mH&Y Scale, modified Hoehn & Yahr Scale; MMSE, Mini-Mental State Examination; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson’s Disease Rating Scale; LED, levodopa-equivalent dose.